206 related articles for article (PubMed ID: 17710669)
1. Multiple novel alterations in Kit tyrosine kinase in patients with gastrointestinally pronounced systemic mast cell activation disorder.
Molderings GJ; Kolck UW; Scheurlen C; Brüss M; Homann J; Von Kügelgen I
Scand J Gastroenterol; 2007 Sep; 42(9):1045-53. PubMed ID: 17710669
[TBL] [Abstract][Full Text] [Related]
2. Somatic c-KIT activating mutation in urticaria pigmentosa and aggressive mastocytosis: establishment of clonality in a human mast cell neoplasm.
Longley BJ; Tyrrell L; Lu SZ; Ma YS; Langley K; Ding TG; Duffy T; Jacobs P; Tang LH; Modlin I
Nat Genet; 1996 Mar; 12(3):312-4. PubMed ID: 8589724
[TBL] [Abstract][Full Text] [Related]
3. Systemic mastocytosis with associated clonal hematological non-mast-cell lineage disease: analysis of clinicopathologic features and activating c-kit mutations.
Pullarkat VA; Bueso-Ramos C; Lai R; Kroft S; Wilson CS; Pullarkat ST; Bu X; Thein M; Lee M; Brynes RK
Am J Hematol; 2003 May; 73(1):12-7. PubMed ID: 12701114
[TBL] [Abstract][Full Text] [Related]
4. Identification of a c-kit exon 8 internal tandem duplication in a feline mast cell tumor case and its favorable response to the tyrosine kinase inhibitor imatinib mesylate.
Isotani M; Tamura K; Yagihara H; Hikosaka M; Ono K; Washizu T; Bonkobara M
Vet Immunol Immunopathol; 2006 Nov; 114(1-2):168-72. PubMed ID: 16908071
[TBL] [Abstract][Full Text] [Related]
5. Detection of mi transcription factor (MITF) mRNA in a case of myelodysplastic syndrome and bone marrow mastocytosis.
Wimazal F; Walchshofer S; Baghestanian M; Chott A; Sperr WR; Kopp C; Sillaber C; Semper H; Horny HP; Tröndle U; Födinger M; Schwarzinger I; Lechner K; Valent P
Wien Klin Wochenschr; 1998 Feb; 110(3):79-88. PubMed ID: 9553202
[TBL] [Abstract][Full Text] [Related]
6. Mast cell leukemia: identification of a new c-Kit mutation, dup(501-502), and response to masitinib, a c-Kit tyrosine kinase inhibitor.
Georgin-Lavialle S; Lhermitte L; Suarez F; Yang Y; Letard S; Hanssens K; Feger F; Renand A; Brouze C; Canioni D; Asnafi V; Chandesris MO; Aouba A; Gineste P; Macintyre E; Mansfield CD; Moussy A; Lepelletier Y; Dubreuil P; Hermine O
Eur J Haematol; 2012 Jul; 89(1):47-52. PubMed ID: 22324351
[TBL] [Abstract][Full Text] [Related]
7. KIT and mastocytosis.
Lim KH; Pardanani A; Tefferi A
Acta Haematol; 2008; 119(4):194-8. PubMed ID: 18566536
[TBL] [Abstract][Full Text] [Related]
8. [Therapeutically relevant mutations in the receptor tyrosine kinase KIT in mastocytosis].
Sotlar K
Verh Dtsch Ges Pathol; 2007; 91():169-76. PubMed ID: 18314612
[TBL] [Abstract][Full Text] [Related]
9. Association of paediatric mastocytosis with a polymorphism resulting in an amino acid substitution (M541L) in the transmembrane domain of c-KIT.
Foster R; Byrnes E; Meldrum C; Griffith R; Ross G; Upjohn E; Braue A; Scott R; Varigos G; Ferrao P; Ashman LK
Br J Dermatol; 2008 Nov; 159(5):1160-9. PubMed ID: 18795925
[TBL] [Abstract][Full Text] [Related]
10. The c-Kit/D816V mutation eliminates the differences in signal transduction and biological responses between two isoforms of c-Kit.
Pedersen M; Rönnstrand L; Sun J
Cell Signal; 2009 Mar; 21(3):413-8. PubMed ID: 19049823
[TBL] [Abstract][Full Text] [Related]
11. Clonal mast cell disorders in patients with systemic reactions to Hymenoptera stings and increased serum tryptase levels.
Bonadonna P; Perbellini O; Passalacqua G; Caruso B; Colarossi S; Dal Fior D; Castellani L; Bonetto C; Frattini F; Dama A; Martinelli G; Chilosi M; Senna G; Pizzolo G; Zanotti R
J Allergy Clin Immunol; 2009 Mar; 123(3):680-6. PubMed ID: 19135713
[TBL] [Abstract][Full Text] [Related]
12. "Occult" mastocytosis with activating c-kit point mutation evolving into systemic mastocytosis associated with plasma cell myeloma and secondary amyloidosis.
Sotlar K; Saeger W; Stellmacher F; Stahmer J; Jäckle S; Valent P; Horny HP
J Clin Pathol; 2006 Aug; 59(8):875-8. PubMed ID: 16873565
[TBL] [Abstract][Full Text] [Related]
13. Comparative analysis of mutation of tyrosine kinase kit in mast cells from patients with systemic mast cell activation syndrome and healthy subjects.
Molderings GJ; Meis K; Kolck UW; Homann J; Frieling T
Immunogenetics; 2010 Dec; 62(11-12):721-7. PubMed ID: 20838788
[TBL] [Abstract][Full Text] [Related]
14. Mastocytosis.
Metcalfe DD
Novartis Found Symp; 2005; 271():232-42; discussion 242-9. PubMed ID: 16605139
[TBL] [Abstract][Full Text] [Related]
15. New aspects of liver abnormalities as part of the systemic mast cell activation syndrome.
Alfter K; von Kügelgen I; Haenisch B; Frieling T; Hülsdonk A; Haars U; Rolfs A; Noe G; Kolck UW; Homann J; Molderings GJ
Liver Int; 2009 Feb; 29(2):181-6. PubMed ID: 18662284
[TBL] [Abstract][Full Text] [Related]
16. Human piebaldism: six novel mutations of the proto-oncogene KIT.
Syrris P; Heathcote K; Carrozzo R; Devriendt K; Elçioglu N; Garrett C; McEntagart M; Carter ND
Hum Mutat; 2002 Sep; 20(3):234. PubMed ID: 12204004
[TBL] [Abstract][Full Text] [Related]
17. Recent advances in the understanding of mastocytosis: the role of KIT mutations.
Orfao A; Garcia-Montero AC; Sanchez L; Escribano L;
Br J Haematol; 2007 Jul; 138(1):12-30. PubMed ID: 17555444
[TBL] [Abstract][Full Text] [Related]
18. Systemic mastocytosis: current classification and novel therapeutic options.
Barbie DA; Deangelo DJ
Clin Adv Hematol Oncol; 2006 Oct; 4(10):768-75. PubMed ID: 17099633
[TBL] [Abstract][Full Text] [Related]
19. Diagnosis and classification of mast cell proliferative disorders: delineation from immunologic diseases and non-mast cell hematopoietic neoplasms.
Valent P; Sperr WR; Schwartz LB; Horny HP
J Allergy Clin Immunol; 2004 Jul; 114(1):3-11; quiz 12. PubMed ID: 15241337
[TBL] [Abstract][Full Text] [Related]
20. Mastocytosis - an update.
Amon U; Hartmann K; Horny HP; Nowak A
J Dtsch Dermatol Ges; 2010 Sep; 8(9):695-711; quiz 712. PubMed ID: 20678151
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]